KNSA (Kiniksa Pharmaceuticals International) Short Interest


KNSA Kiniksa Pharmaceuticals International PLC KNSA
56 GF Score
Price $59.72
GF Value $47.89
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

KNSA vs AMRX, INDV, SUPN: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Short Interest distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Short Interest falls into.


KNSA
56GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $59.72 is trading 24.7% above its estimated GF Value™ of $47.89. GuruFocus considers Kiniksa Pharmaceuticals International to be Modestly Overvalued.

Key valuation signals for KNSA:

  • Short Interest:
  • GF Value™: $47.89 vs. price of $59.72 (24.7% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
56GF Score

Get the complete analysis for KNSA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.72
Price
$47.89
GF Value